OXERVATE (cenegermin), recombinant human nerve growth factor

Substantial clinical benefit in the treatment of neurotrophic keratitis and minor clinical added value in usual management

• OXERVATE has Marketing Authorisation in the treatment of adults with moderate (persistent epithelial lesions) or severe (corneal ulcer) neurotrophic keratitis.
• Its superiority compared with placebo (lubricant excipient) has been demonstrated on the percentage of patients with complete healing after 8 weeks of treatment.
• It is a first-line treatment in patients for whom initial conventional measures (including elimination of toxic products and lubrication) have been insufficient.